Esophagus : official journal of the Japan Esophageal Society · 2026
Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tamaoki Masashi, Yokoyama Akira, Katada Chikatoshi, Hirohashi Kenshiro, Mitani Yosuke, Amanuma Yusuke, Horimatsu Takahiro, Higuchi Hirokazu, Yamahigashi Natsuko, Nomura Motoo, Inoo Hiroyuki, Sakanaka Katsuyuki, Nikaido Mitsuhiro, Shimizu Takahiro, Kishimoto Yo, Tsunoda Shigeru, Obama Kazutaka, Ohashi Shinya, Muto Manabu
Аннотация
BACKGROUND: Talaporfin sodium photodynamic therapy (Talaporfin-PDT) shows a high local complete response (L-CR) rate for local failure after chemoradiotherapy in esophageal cancer; however, some patients do not achieve L-CR. We investigated the treatment resistance factors associated with Talaporfin-PDT for local control.
METHODS: This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model.
RESULTS: The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3-76.6). During the median follow-up of 17.8 months (range, 1.7-69.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% (P = 0.008), 64.6% vs. 0% (P < 0.001), and 97.0% vs. 85.7% (P = 0.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051-30.124, P = 0.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% (P = 0.015) and 85.7% vs. 94.6% (P = 0.015), respectively.
CONCLUSIONS: Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.
METHODS: This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model.
RESULTS: The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3-76.6). During the median follow-up of 17.8 months (range, 1.7-69.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% (P = 0.008), 64.6% vs. 0% (P < 0.001), and 97.0% vs. 85.7% (P = 0.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051-30.124, P = 0.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% (P = 0.015) and 85.7% vs. 94.6% (P = 0.015), respectively.
CONCLUSIONS: Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.